(MedPage Today) — The oral GLP-1 receptor agonist semaglutide (Rybelsus) did not slow Alzheimer’s disease progression in the highly awaited EVOKE phase III trials, Novo Nordisk announced Monday.
The company shared topline results from the 2-year…
Source link : https://www.medpagetoday.com/neurology/alzheimersdisease/118689
Author :
Publish date : 2025-11-24 22:02:00
Copyright for syndicated content belongs to the linked Source.
